ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

To Review Cancer Bioinformatics Grid

November 12, 2010

Wiernik Loses Post At Einstein Following Unauthorized Trials

November 5, 1993

NCI To Expand Funds for Cancer Centers, SPOREs, Director Tells House Appropriators

March 29, 2002

WHI Investigators Reiterate: Breast Cancer, CHD Risks Too Great For Routine HT Use

November 2, 2002

New Awards for New Investigators To Replace R-23 Grants

November 8, 1985

Ovariectomy Without HRT Increases Death Rate

September 29, 2006